HUTCHMED (China) Ltd. announced the publication of results from the Phase III SACHI clinical trial in The Lancet. The study evaluated the efficacy of the combination of savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®) in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) who developed MET amplification after progression on first-line EGFR tyrosine kinase inhibitor (TKI) therapy. The trial met its primary endpoint of progression-free survival $(PFS)$, with the combination therapy demonstrating a median PFS of 8.2 months compared to 4.5 months with chemotherapy in the intention-to-treat population. The results were presented in January 2025 during a planned interim analysis and have now been published. The combination of savolitinib and osimertinib was approved in China in June 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9625417) on January 14, 2026, and is solely responsible for the information contained therein.